November 12, 2020 10:34 AM EST
Pharma
FDA+

French health prod­ucts agency yanked in­to le­gal bat­tle over birth de­fects caused by Sanofi's De­pakine

Nicole DeFeudis

Editor

A probe in­to Sanofi’s epilep­sy drug De­pakine has now en­tan­gled France’s Na­tion­al Med­i­cines and Health Prod­ucts Agency (ANSM), which was in­dict­ed on Wednes­day for “in­juries …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force in lat­est job cuts

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

A service from the Financial Times